285 related articles for article (PubMed ID: 29488065)
1. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
3. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
4. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma.
Harada K; Ida S; Baba Y; Ishimoto T; Kosumi K; Tokunaga R; Izumi D; Ohuchi M; Nakamura K; Kiyozumi Y; Imamura Y; Iwatsuki M; Iwagami S; Miyamoto Y; Sakamoto Y; Yoshida N; Watanabe M; Baba H
Dis Esophagus; 2016 Aug; 29(6):627-33. PubMed ID: 26123787
[TBL] [Abstract][Full Text] [Related]
6. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
7. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
8. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
10. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
[TBL] [Abstract][Full Text] [Related]
13. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
[TBL] [Abstract][Full Text] [Related]
14. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
15. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
[TBL] [Abstract][Full Text] [Related]
16. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
[TBL] [Abstract][Full Text] [Related]
17. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma.
Saeki H; Morita M; Nakashima Y; Sonoda H; Hashimoto K; Egashira A; Oki E; Ohga T; Kakeji Y; Maehara Y
Anticancer Res; 2011 Sep; 31(9):3073-7. PubMed ID: 21868562
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
20. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]